Search results for: germany

Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more
Germany’s Draft SHI Reform Bill: Implications fo...

Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment ...

Read more
The transformation of healthcare through personali...

The rise of personalised medicine is revolutionizing healthcare, prompting a re-evaluation of tradit...

Read more
The Bundesrat rejected confidential rebates propos...

The German government’s proposal to keep negotiated confidential rebates was rejected by the feder...

Read more
Biosimilar Switching in Germany from March 15, 202...

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...

Read more
Confidential rebates are raising concerns in Germa...

Proposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...

Read more
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more
To improve Germany’s attractiveness, confidentia...

Germany’s Health minister has announced that publicly listed AMNOG rebates could be replaced by co...

Read more
ISPOR Europe 2023: Evaluation and Reimbursement of...

Our study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...

Read more
Germany’s Health Ministry Shifts Focus to Di...

Germany is reshaping its Ministry of Health to prioritize the prevention of diseases like cancer, de...

Read more
Older

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch